Evidence map›Paper›PMID 30675199›Full record

ArticleOncology letters2019

miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases.

Jue Liu, Xiaobo Zhang, Yuliang Huang, Qunfeng Zhang, Jianbin Zhou, Xiaodi Zhang, Xiaoxu Wang

RetractedOpen access · diamondAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Mechanisms of apoptosis-related non-coding RNAs in ovarian cancer: a narrative review.Apoptosis : an international journal on programmed cell death · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. MicroRNAs in T Cell-Immunotherapy.International journal of molecular sciences · 2022
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jue LiuDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
Xiaobo ZhangDepartment of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Yuliang HuangDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
Qunfeng ZhangDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
Jianbin ZhouDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
Xiaodi ZhangDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
Xiaoxu WangDepartment of Joint Surgery, The Second Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China.
University of South China · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin is a first-line chemotherapy drug that is commonly used in the treatment of epithelial ovarian cancer (EOC). However, insensitivity to cisplatin markedly influences the outcomes of chemotherapy. MicroRNAs (miRNAs/miRs) have been demonstrated to modulate drug resistance in a number of types of cancer. The aim of the present study was to investigate the key miRNAs involved in modulating drug resistance in ovarian cancer cells. miR-200b and miR-200c were identified to be frequently deregulated in ovarian cancer. Upregulation of miR-200b and miR-200c promoted EOC cell death in the presence of cisplatin. Upregulation of miR-125b-5p significantly decreased tumor growth in combination with cisplatin in a mouse model. Significantly, miR-200b and miR-200c reversed cisplatin resistance by targeting DNA methyltransferases (DNMTs) (directly targeting DNMT3A/DNMT3B and indirectly targeting DNMT1 via specificity protein 1). These results indicate that miR-200b- and miR-200c-mediated regulation of DNMTs serves a crucial function in the cellular response to cisplatin. miR-200b- and miR-200c-mediated downregulation of DNMTs may improve chemotherapeutic efficacy by increasing the sensitivity of cancer cells and thus may have an impact on ovarian cancer therapy.

Indexed as

DNA methyltransferasesmicroRNA-200bmicroRNA-200covarian cancer

Identifiers

PMID30675199
PMCPMC6341622
OpenAlexW2900975497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.